131 related articles for article (PubMed ID: 30836319)
1. Combined QSAR/QSPR and molecular docking study on fluoroquinolones to reduce biological enrichment.
Zhao X; Zhao Y; Ren Z; Li Y
Comput Biol Chem; 2019 Apr; 79():177-184. PubMed ID: 30836319
[TBL] [Abstract][Full Text] [Related]
2. Piperazine-azole-fluoroquinolone hybrids: Conventional and microwave irradiated synthesis, biological activity screening and molecular docking studies.
Mermer A; Faiz O; Demirbas A; Demirbas N; Alagumuthu M; Arumugam S
Bioorg Chem; 2019 Apr; 85():308-318. PubMed ID: 30654222
[TBL] [Abstract][Full Text] [Related]
3. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
Oizumi N; Kawabata S; Hirao M; Watanabe K; Okuno S; Fujiwara T; Kikuchi M
J Infect Chemother; 2001 Sep; 7(3):191-4. PubMed ID: 11810583
[TBL] [Abstract][Full Text] [Related]
4. Molecular Modeling Studies of Novel Fluoroquinolone Molecules.
Allaka TR; Katari NK; Veeramreddy V; Anireddy JS
Curr Drug Discov Technol; 2018; 15(2):109-122. PubMed ID: 28875852
[TBL] [Abstract][Full Text] [Related]
5. Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases.
Richter SN; Giaretta G; Comuzzi V; Leo E; Mitchenall LA; Fisher LM; Maxwell A; Palumbo M
Nucleic Acids Res; 2007; 35(18):6075-85. PubMed ID: 17766248
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of novel N-1 fluoroquinolone derivatives: Probing for binding contact with the active site tyrosine of gyrase.
Towle TR; Kulkarni CA; Oppegard LM; Williams BP; Picha TA; Hiasa H; Kerns RJ
Bioorg Med Chem Lett; 2018 Jun; 28(10):1903-1910. PubMed ID: 29661533
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Pyrido[2,3-
Hu Y; Shi H; Zhou M; Ren Q; Zhu W; Zhang W; Zhang Z; Zhou C; Liu Y; Ding X; Shen HC; Yan SF; Dey F; Wu W; Zhai G; Zhou Z; Xu Z; Ji Y; Lv H; Jiang T; Wang W; Xu Y; Vercruysse M; Yao X; Mao Y; Yu X; Bradley K; Tan X
J Med Chem; 2020 Sep; 63(17):9623-9649. PubMed ID: 32787097
[TBL] [Abstract][Full Text] [Related]
9. The C7-aminomethylpyrrolidine group rescues the activity of a thio-fluoroquinolone.
Lentz SRC; Chheda PR; Oppegard LM; Towle TR; Kerns RJ; Hiasa H
Biochimie; 2019 May; 160():24-27. PubMed ID: 30763638
[TBL] [Abstract][Full Text] [Related]
10. Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones.
Oppegard LM; Streck KR; Rosen JD; Schwanz HA; Drlica K; Kerns RJ; Hiasa H
Antimicrob Agents Chemother; 2010 Jul; 54(7):3011-4. PubMed ID: 20404126
[TBL] [Abstract][Full Text] [Related]
11. Highly biodegradable fluoroquinolone derivatives designed using the 3D-QSAR model and biodegradation pathways analysis.
Hou Y; Zhao Y; Li Q; Li Y
Ecotoxicol Environ Saf; 2020 Mar; 191():110186. PubMed ID: 31954922
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR and docking studies of flavonoids as potent Escherichia coli inhibitors.
Fang Y; Lu Y; Zang X; Wu T; Qi X; Pan S; Xu X
Sci Rep; 2016 Apr; 6():23634. PubMed ID: 27049530
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
Gjorgjieva M; Tomašič T; Barančokova M; Katsamakas S; Ilaš J; Tammela P; Peterlin Mašič L; Kikelj D
J Med Chem; 2016 Oct; 59(19):8941-8954. PubMed ID: 27541007
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.
Surivet JP; Zumbrunn C; Rueedi G; Hubschwerlen C; Bur D; Bruyère T; Locher H; Ritz D; Keck W; Seiler P; Kohl C; Gauvin JC; Mirre A; Kaegi V; Dos Santos M; Gaertner M; Delers J; Enderlin-Paput M; Boehme M
J Med Chem; 2013 Sep; 56(18):7396-415. PubMed ID: 23968485
[TBL] [Abstract][Full Text] [Related]
16. Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV.
Nakase K; Sakuma Y; Nakaminami H; Noguchi N
Anaerobe; 2016 Dec; 42():166-171. PubMed ID: 27793740
[TBL] [Abstract][Full Text] [Related]
17. Identification of secondary metabolites from Crescentia cujete as promising antibacterial therapeutics targeting type 2A topoisomerases through molecular dynamics simulation.
Aribisala JO; Abdulsalam RA; Dweba Y; Madonsela K; Sabiu S
Comput Biol Med; 2022 Jun; 145():105432. PubMed ID: 35344868
[TBL] [Abstract][Full Text] [Related]
18. Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site.
Franco-Ulloa S; La Sala G; Miscione GP; De Vivo M
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29401640
[TBL] [Abstract][Full Text] [Related]
19. Molecular docking, discovery, synthesis, and pharmacological properties of new 6-substituted-2-(3-phenoxyphenyl)-4-phenyl quinoline derivatives; an approach to developing potent DNA gyrase inhibitors/antibacterial agents.
Alagumuthu M; Arumugam S
Bioorg Med Chem; 2017 Feb; 25(4):1448-1455. PubMed ID: 28094220
[TBL] [Abstract][Full Text] [Related]
20. Structural Insights into the Fluoroquinolone Resistance Mechanism of Shigella flexneri DNA Gyrase and Topoisomerase IV.
Tamanna ; Ramana J
Microb Drug Resist; 2016 Jul; 22(5):404-11. PubMed ID: 26859259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
